ZAM-CS, a novel chimeric endolysin with enhanced stability and rapid action against methicillin-resistant Staphylococcus aureus.

ABSTRACT:

Background

The rising occurrence of antibiotic resistance in Staphylococcus aureus significantly complicates its treatment. Endolysins are now recognized as a promising substitute for antibiotics in combating multidrug-resistant bacteria. In this research, a novel chimeric endolysin named ZAM-CS was engineered and assessed to achieve enhanced stability, solubility, and rapid bactericidal activity. This was accomplished by combining the catalytic domain of the SAL-1 endolysin with the peptidoglycan binding domain of lysostaphin.

Results

Expression and purification outcomes indicated that ZAM-CS exhibited significant solubility, with a yield of approximately 23 mg/L. ZAM-CS demonstrated high stability under various temperature conditions and retained most of its activity in bo

SUBMITTER: Ahmadbeigi Y 

PROVIDER: S-EPMC12144729 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature